Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Locus Pharmaceuticals has entered into a research agreement with Amgen to design novel small molecule compounds with activity against a target identified by Amgen.
Subscribe to our email newsletter
Computational drug design company Locus has successfully applied its novel technology in six external collaborations to date, which have demonstrated significant advantages in terms of novelty, cost and speed of development.
All of Locus’ internal development programs emanate from its computational technology and are focused on oral drug therapies, principally in cancer and inflammation.
“We are very pleased to be working with Amgen on this project and expanding our virtual fragment-based design approach,” said Dr Jeffrey Wiseman, vice president of technology & informatics at Locus. “Given our past molecular design experience across 10 classes of protein targets, we are confident that we will identify novel chemical classes of inhibitors for Amgen.”
Financial and other terms of the agreement were not disclosed.